CPRX - Catalyst Pharma ends momentum as Roth downgrades

• The shares of Catalyst Pharmaceuticals ( NASDAQ: CPRX ) dropped ~8% in the morning hours Wednesday to record the biggest intraday loss in over three months after Roth Capital Partners downgraded the commercial stage biotech to Neutral from Buy.
• The analyst Scott Henry attributes his downgrade to the “strong run-up,” in company shares, and he notes, “CPRX is hitting on all cylinders.” Yet, with a $15.50 per share target for the stock, he cites the need to see a “greater upside to maintain our Buy rating.”
• Over the past 12 months, CPRX has more than doubled in value outperforming the broader market, as shown in this graph.
• Despite a Hold rating on CPRX, Seeking Alpha contributor Bret Jensen argued in a recent article on Catalyst ( CPRX ) that the company “is obviously executing well and is not unreasonably expensive on an earnings basis given its growth.”

For further details see: